innerbuddies gut microbiome testing

Gut Microbiome and Gestational Diabetes (GDM) in Pregnancy-Related Dysglycemia

Pregnancy is a natural metabolic shift—but for some people, that shift can tip into dysglycemia and ultimately gestational diabetes (GDM). A growing body of research suggests that the gut microbiome—your community of trillions of microbes and their metabolites—may help determine how efficiently your body regulates glucose during pregnancy, influencing insulin sensitivity and inflammation.

In GDM, studies consistently point to characteristic microbiome changes: altered diversity, shifts in key bacterial groups, and differences in metabolite profiles such as short-chain fatty acids (SCFAs), bile acids, and other microbial-derived compounds. These microbial signals can affect host glucose control by shaping gut barrier integrity, modulating immune pathways, and influencing insulin signaling—mechanisms that can either support metabolic resilience or contribute to insulin resistance during pregnancy.

Understanding the “microbiome–metabolism” link offers a practical perspective on pregnancy dysglycemia. Instead of focusing only on glucose readings, researchers are exploring how dietary patterns, fiber intake, and gut-friendly nutrients may promote a healthier microbial ecosystem—potentially improving insulin sensitivity and maternal glucose regulation. Explore how these microbiome pathways connect to GDM risk and what actionable steps may help support healthier outcomes for pregnancy-related dysglycemia.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Quick Summary

Pregnancy-related dysglycemia

Pregnancy-related dysglycemia encompasses impaired glucose tolerance and gestational diabetes (GDM), arising from the normal rise in insulin resistance during pregnancy and individual gut microbiome patterns. The gut microbiome can influence glucose regulation through short-chain fatty acid production, gut barrier function, inflammation, bile acid signaling, and enteroendocrine pathways, with distinct microbial patterns often observed in women who develop GDM. This microbiome-glycemic link helps explain higher fasting glucose and postprandial glucose fluctuations seen in pregnancy lumbosacral contexts and underscores the potential for microbiome-informed risk assessment.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Key takeaways

  1. Low beneficial SCFA-producing taxa (e.g., Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia spp., Butyricicoccus pullicaecorum, Eubacterium rectale, Bifidobacterium spp., Blautia spp., Christensenellaceae) are linked to reduced butyrate/acetate/propionate production, weakening gut barrier and promoting insulin resistance and higher fasting/postprandial glucose in pregnancy.
  2. Elevated pro-inflammatory or dysbiotic taxa (e.g., Enterococcus spp., Streptococcus spp., Ruminococcus gnavus group, Parabacteroides spp., Dialister spp., Escherichia/Shigella, Adlercreutzia) are associated with increased gut permeability and endotoxemia, driving inflammation and worsened glucose control during gestation.
  3. Microbiome-driven bile acid metabolism and signaling (FXR/TGR5) shift insulin sensitivity and hepatic glucose output as microbial communities alter bile acid pools, linking dysbiotic patterns to glucose dysregulation.
  4. Microbial metabolites and enteroendocrine signaling (including GLP-1 pathways) modulated by gut microbes influence insulin secretion and glucose absorption, shaping gestational glucose tolerance.
  5. Diet-microbiome interactions matter: fiber-rich, plant-diverse, Mediterranean-style diets support SCFA-producing microbes and balanced bile acid signaling, which may improve glycemic control in pregnancy, whereas ultra-processed diets favor dysglycemia-prone patterns.
  6. Microbiome testing can help risk-stratify pregnancy-related dysglycemia and guide personalized nutrition to promote beneficial SCFA producers and barrier integrity, potentially reducing fasting and postprandial glucose fluctuations.
innerbuddies gut microbiome testing

Condition Overview

Gestational diabetes mellitus (GDM) - Pregnancy-related dysglycemia

Pregnancy-related dysglycemia refers to abnormal glucose regulation that can range from impaired glucose tolerance to gestational diabetes (GDM). During pregnancy, normal hormonal shifts (including increased insulin resistance driven by placental hormones) can overwhelm the body’s ability to produce enough insulin, leading to higher blood glucose levels. What has become increasingly clear is that the gut microbiome—along with diet patterns that shape it—may influence how efficiently the body regulates glucose, including pathways related to inflammation, gut barrier function, bile acid signaling, and short-chain fatty acid (SCFA) production.

Research suggests that women who develop GDM often show distinct gut microbial patterns compared with those who maintain normal glucose regulation. These differences can affect metabolic health through several mechanisms: altered microbial fermentation (which changes SCFA profiles like butyrate, acetate, and propionate), changes in gut-derived metabolites that influence insulin sensitivity, and increased gut permeability that may promote low-grade inflammation. Additionally, microbiota can modulate bile acids and enteroendocrine signaling, both of which are tightly linked to glucose metabolism during pregnancy. Taken together, microbiome shifts may contribute to the degree of insulin resistance experienced in gestation.

Understanding the gut microbiome’s role in pregnancy dysglycemia opens the door to earlier risk identification and more targeted, gut-friendly prevention strategies. Diet is a primary lever because fiber and plant diversity generally support beneficial microbes and SCFA production, while high intake of ultra-processed foods may favor pathways associated with metabolic dysregulation. Practical approaches often emphasize a Mediterranean-style pattern, adequate fiber (from whole grains, legumes, vegetables, fruits, and nuts), and minimizing highly refined carbohydrates—strategies shown to support microbiome resilience. While microbiome-based therapies are still an evolving field, aligning nutrition with microbial health may help support healthier maternal glucose regulation and potentially improve pregnancy outcomes.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Common Symptoms

  • Higher-than-expected fasting blood glucose levels
  • Elevated blood glucose after meals (postprandial hyperglycemia)
  • Increased insulin resistance during pregnancy (difficulty maintaining normal glucose)
  • Gestational diabetes diagnosis or borderline glucose test results (e.g., abnormal oral glucose tolerance test)
  • Excessive thirst and frequent urination (especially when glucose is high)
  • Unexplained fatigue or reduced energy related to blood sugar fluctuations
  • Blurred vision or transient vision changes during periods of high glucose
innerbuddies gut microbiome testing

Who is it relevant for?

This is relevant for pregnant people who notice pregnancy-related dysglycemia—especially those with borderline or abnormal glucose screening results (like an impaired oral glucose tolerance test) or who are newly diagnosed with gestational diabetes (GDM). It’s also a fit for anyone concerned about persistently higher fasting glucose, repeated post-meal blood sugar spikes, or a clear increase in insulin resistance during pregnancy, whether or not medication has started yet.

It may also be especially helpful for individuals who experience common glucose-related symptoms during pregnancy, such as excessive thirst and frequent urination, unexplained fatigue tied to blood sugar fluctuations, or transient blurred vision when glucose runs high. If these symptoms show up alongside lab findings or home glucose readings, a gut-microbiome-informed nutrition approach may support earlier risk awareness and better glucose stability.

Lastly, this is relevant for those interested in the “why” behind glucose changes in pregnancy—particularly women who want to optimize diet patterns for gut health. Because the gut microbiome can influence glucose regulation through mechanisms like SCFA production (e.g., butyrate/propionate), gut barrier integrity, inflammation signaling, and bile acid–enteroendocrine pathways, it can be a strong framework for people who aim to use fiber-rich, minimally processed, Mediterranean-style eating to support healthier microbial function during pregnancy.

innerbuddies gut microbiome testing

Prevalence Summary

Pregnancy-related dysglycemia (ranging from impaired glucose tolerance to gestational diabetes mellitus, GDM) is common worldwide and is a major metabolic complication of pregnancy. The prevalence of GDM is typically reported at roughly 5–14% of pregnancies globally, with higher rates in populations with greater background risk for type 2 diabetes. Because impaired glucose tolerance and “borderline” abnormal screening results often cluster around the same metabolic physiology, the overall share of pregnant people affected by dysglycemia (not just those meeting full GDM criteria) is generally even larger than GDM alone.

Clinically, many cases come to light through patterns consistent with the common symptoms of pregnancy dysglycemia—such as higher-than-expected fasting blood glucose, elevated post-meal glucose (postprandial hyperglycemia), and difficulty maintaining normal insulin sensitivity during pregnancy. When routine screening is performed, abnormal results on an oral glucose tolerance test (OGTT) can be found in a meaningful fraction of patients, with reported estimates that frequently fall in the same broad range as GDM screening positivity. This means that thousands of pregnancies per 100,000 people will experience glucose regulation abnormalities each year, whether diagnosed as GDM or identified as impaired glucose tolerance.

At the population level, the prevalence also tracks with risk factors that commonly influence insulin resistance and metabolic stress during pregnancy—such as prior dysglycemia, higher pre-pregnancy BMI, family history of type 2 diabetes, and certain ethnic backgrounds. These factors also overlap with dietary patterns that shape the gut microbiome (e.g., lower fiber, higher ultra-processed food intake), which may further contribute to dysglycemia risk. As a result, prevalence can vary substantially by region and demographics, but the overall public health burden remains significant: approximately 1 in 20 to 1 in 10 pregnancies are affected by GDM-like dysglycemia worldwide, with additional cases captured under “borderline” or pre-GDM glucose intolerance on screening.

innerbuddies gut microbiome testing

Gut Microbiome & Gestational Diabetes (GDM): Pregnancy Dysglycemia Links

Pregnancy-related dysglycemia, including gestational diabetes (GDM), is increasingly linked to the gut microbiome because gut microbes influence glucose regulation through multiple metabolic signaling pathways. During pregnancy, placental hormones naturally increase insulin resistance; for some people, the gut ecosystem shifts in ways that further affect how efficiently glucose is handled. Research shows that women who develop GDM often have distinct microbial community patterns compared with those who maintain normal glucose control, which may alter microbial fermentation and the balance of gut-derived metabolites that support insulin sensitivity.

Mechanistically, dysglycemia may be connected to changes in short-chain fatty acid (SCFA) production—especially butyrate, acetate, and propionate—which are produced when gut bacteria ferment dietary fiber. A microbiome less supportive of healthy SCFA profiles can contribute to worsened insulin resistance and more pronounced post-meal glucose elevations. Additionally, gut permeability changes can promote low-grade inflammation, and inflammation itself can impair insulin signaling. These gut-related effects may help explain symptoms such as higher-than-expected fasting glucose, elevated postprandial hyperglycemia, and the overall difficulty maintaining normal glucose regulation during pregnancy.

The gut microbiome also interacts with bile acid metabolism and enteroendocrine signaling, both of which are tightly tied to glucose homeostasis. Microbes can modify bile acids that then activate metabolic receptors involved in insulin sensitivity, while microbial metabolites can influence hormone pathways that regulate appetite, insulin release, and glucose absorption. Because diet strongly shapes the microbiome, gut-friendly eating patterns—like Mediterranean-style meals with high fiber and diverse plant foods—may support a resilient microbial community and healthier SCFA and bile acid signaling. This is relevant to the clinical picture of GDM diagnosis or borderline glucose test results, and to day-to-day symptoms such as excessive thirst, frequent urination, fatigue, and transient vision changes when blood glucose is high.

Order Your Gut Microbiome Test Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Mechanisms Involved

  • SCFA production shifts (butyrate, acetate, propionate): Microbiome changes can alter fiber fermentation, reducing insulin-sensitizing SCFA signaling and worsening post-meal glucose control.
  • Gut permeability and low-grade inflammation: Dysbiosis can weaken gut barrier integrity, increasing endotoxin translocation and triggering inflammatory pathways that impair insulin receptor signaling.
  • Bile acid metabolism and FXR/TGR5 signaling: Gut microbes convert and remodel bile acids, which regulate glucose homeostasis via metabolic receptors that influence insulin sensitivity and hepatic glucose output.
  • Enteroendocrine hormone modulation: Microbial metabolites can affect gut-brain and gut endocrine signaling (e.g., GLP-1 and related pathways), influencing insulin secretion, appetite regulation, and glucose absorption.
  • Altered fermentation metabolites beyond SCFAs: Changes in amino acid and other metabolite profiles can promote metabolic stress and influence insulin sensitivity, contributing to elevated fasting and postprandial glucose.
  • Microbiome–diet interaction amplifying pregnancy insulin resistance: Pregnancy hormones already increase insulin resistance; diet-driven microbiome shifts can further impair metabolic flexibility, making dysglycemia more likely or harder to correct.
innerbuddies gut microbiome testing

Mechanism Explainer

Pregnancy naturally increases insulin resistance due to placental hormones, but the gut microbiome can tilt glucose regulation in either a supportive or harmful direction. In women who develop gestational diabetes (GDM), gut microbial community patterns often differ from those seen in normal pregnancy glucose control, suggesting that diet-shaped ecosystem changes can alter how efficiently the body handles glucose. These shifts can change fermentation outputs and downstream metabolic signaling, contributing to higher fasting glucose and stronger post-meal glucose spikes.

A central pathway is altered production of short-chain fatty acids (SCFAs) such as butyrate, acetate, and propionate, which are generated when gut bacteria ferment dietary fiber. When the microbiome composition favors less beneficial fermentation, SCFA levels and signaling may weaken—affecting insulin sensitivity and glucose tolerance. At the same time, dysbiosis may increase gut permeability, allowing inflammatory triggers (like endotoxin) to cross a weakened gut barrier and promote low-grade inflammation, which can impair insulin receptor signaling and worsen insulin resistance.

Beyond SCFAs, gut microbes interact with bile acid metabolism and enteroendocrine signaling—two systems tightly linked to glucose homeostasis. Microbes modify bile acids that activate metabolic receptors (including FXR/TGR5), influencing hepatic glucose output and insulin sensitivity. Microbial metabolites can also affect hormone pathways such as GLP-1–related signaling, thereby shaping insulin secretion and glucose absorption. Together with fermentation byproducts beyond SCFAs, these gut-driven mechanisms can amplify pregnancy-related insulin resistance, making dysglycemia more likely and harder to manage unless the diet supports a healthier microbial and metabolite profile.

innerbuddies gut microbiome testing

Microbial Patterns Summary

Pregnancy-related dysglycemia—especially gestational diabetes (GDM)—is commonly associated with gut microbiome shifts that alter community structure and metabolic output compared with pregnancies that maintain normal glucose regulation. Women who later develop GDM often show differences in the relative abundance of key bacterial groups and overall diversity, suggesting that diet-driven ecosystem changes can influence how efficiently glucose is processed. These microbial patterns can translate into altered fermentation profiles, less favorable metabolite signaling, and a reduced capacity to support insulin sensitivity during a period when placental hormones already increase insulin resistance.

A central feature of these dysglycemia-associated patterns is variation in short-chain fatty acid (SCFA) production, including butyrate, acetate, and propionate. SCFAs are generated when gut bacteria ferment dietary fiber, and they help regulate glucose homeostasis through effects on gut barrier function, inflammation, and metabolic signaling. When the microbiome composition supports less beneficial fermentation, SCFA availability and signaling can shift in a way that weakens insulin sensitivity and contributes to higher fasting glucose and more pronounced post-meal glucose spikes.

Dysglycemia-associated microbiomes also tend to relate to changes in gut permeability, low-grade inflammation, bile acid metabolism, and enteroendocrine signaling. Microbial alterations can promote a more permeable intestinal environment, allowing inflammatory triggers such as bacterial endotoxin to contribute to cytokine-driven impairment of insulin receptor function. In parallel, microbes can modify bile acids that activate metabolic receptors (e.g., FXR/TGR5) and influence signaling pathways involved in insulin secretion and glucose absorption—often through GLP-1–related mechanisms—creating a coordinated gut-to-host environment that can amplify pregnancy-related insulin resistance.

innerbuddies gut microbiome testing

Low beneficial taxa

  • Akkermansia muciniphila
  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Butyricicoccus pullicaecorum
  • Eubacterium rectale
  • Bifidobacterium spp.
  • Blautia spp.
  • Christensenellaceae (family)
innerbuddies gut microbiome testing

Elevated / overrepresented taxa

  • Enterococcus spp.
  • Streptococcus spp.
  • Ruminococcus gnavus group
  • Parabacteroides spp.
  • Dialister spp.
  • Bacteroides spp.
  • Escherichia/Shigella
  • Actinobacteria (e.g., Adlercreutzia spp.)
innerbuddies gut microbiome testing

Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis pathways (butyrate, acetate, propionate) via dietary fiber fermentation
  • Gut barrier integrity and epithelial mucus/via mucin degradation/turnover (e.g., pathways linked to Akkermansia-associated mucosal support)
  • Lipopolysaccharide (LPS) detoxification and endotoxin-driven inflammatory signaling (gut permeability–associated inflammation) influencing insulin receptor function
  • Bile acid metabolism and secondary bile acid formation that modulate FXR/TGR5 signaling (bile acid–host metabolic regulation)
  • Enteroendocrine signaling capacity through microbial metabolites affecting GLP-1/PYY signaling (microbe–gut–brain axis influencing insulin secretion)
  • Carbohydrate fermentation and glucose/propionate/acetate flux balance affecting host gluconeogenesis and insulin sensitivity
  • Microbial community oxidative stress response and pro-inflammatory metabolite production (e.g., stress/fermentation-associated pathways enriched with dysbiosis-associated taxa)
innerbuddies gut microbiome testing

Diversity note

Pregnancy-related dysglycemia, including gestational diabetes (GDM), is often accompanied by measurable shifts in gut microbiome composition and a change in overall diversity compared with pregnancies that maintain normal glucose regulation. Across studies, women who develop GDM tend to show a distinct community structure—sometimes characterized by reduced microbial diversity and altered relative abundance of key bacterial groups—suggesting that the ecosystem becomes less resilient during the period when placental hormones already increase insulin resistance.

These diversity changes are meaningful because they correlate with differences in how efficiently gut microbes ferment dietary substrates. When the microbiome shifts away from taxa that support beneficial fermentation, the balance of microbial metabolic output—particularly short-chain fatty acids (SCFAs) like butyrate, acetate, and propionate—can become less favorable for glucose control. That functional shift may contribute to higher fasting glucose and greater post-meal glucose excursions, reflecting a reduced microbiome capacity to support insulin sensitivity through gut barrier, inflammatory, and signaling pathways.

Dysglycemia-associated microbial diversity patterns also tend to coincide with changes in gut ecosystem interactions that influence bile acid metabolism and gut–hormone signaling. A less supportive microbial community may be linked to greater gut permeability and low-grade inflammation, which can further impair insulin signaling. At the same time, altered microbial handling of bile acids and downstream enteroendocrine cues (including GLP-1–related pathways) can reinforce the host’s tendency toward dysregulated glucose metabolism during pregnancy.


Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail in pregnancy-related dysglycemia because they don’t account for the specific gut ecosystem shifts that emerge in this hormonal window. In pregnancy, placental hormones already increase insulin resistance, and for some people the microbiome changes in parallel—altering community diversity and the balance of key bacterial groups that determine fermentation output. A “one-size-fits-all” approach (e.g., general probiotic use, broad calorie reduction, or standard supplements) may not match the direction of a woman’s dysbiosis, so it won’t reliably restore the gut functions most tied to glucose control, such as metabolite signaling and post-meal glucose handling.

    Another reason generic strategies underperform is that they usually target symptoms or single nutrients without correcting the underlying metabolic signaling loop involving short-chain fatty acids (SCFAs). In dysglycemia-associated microbiomes, the capacity to generate beneficial SCFAs—especially butyrate, acetate, and propionate—can be impaired due to differences in fiber fermentation patterns and substrate availability. Without changing the specific dietary drivers and gut ecology that govern SCFA production, “generic fiber” or “generic prebiotics” may not reach the right fermentation pathways or may be poorly tolerated, leaving insulin sensitivity largely unchanged.

    Finally, many generic solutions ignore that gut permeability, inflammation, bile acid metabolism, and enteroendocrine signaling are interlinked with glucose regulation and vary substantially between individuals. Microbiome-driven changes in gut barrier integrity can increase low-grade inflammation, which in turn can blunt insulin receptor signaling; meanwhile, microbial modification of bile acids influences metabolic receptors involved in insulin sensitivity and GLP-1–related pathways. If an intervention doesn’t meaningfully influence these host–microbe signaling networks, improvements in fasting glucose or postprandial excursions may be inconsistent—even if the plan looks “healthy” in a general sense.

  • Common mistakes

    • Using one-size-fits-all probiotic regimens without matching dysglycemia-associated community shifts (wrong strains may not restore the fermentation profile tied to glucose regulation).
    • Relying on generic “more fiber” or broad prebiotics without targeting the specific fermentation pathways and SCFA outputs (butyrate, acetate, propionate) that appear altered in GDM-risk microbiomes.
    • Assuming dietary changes alone will work without considering pregnancy-specific insulin-resistance physiology driven by placental hormones that interacts with microbiome function.
    • Ignoring individuality in gut permeability, low-grade inflammation, bile acid metabolism, and enteroendocrine signaling—so interventions don’t meaningfully adjust the gut-to-host metabolic signaling loop behind insulin sensitivity and GLP-1 effects.
    • Targeting single nutrients or symptoms (e.g., cutting calories or focusing on one macronutrient) instead of correcting the underlying host–microbe SCFA signaling and post-meal glucose handling mechanisms.
    • Not addressing diet–microbiome substrate mismatch (e.g., prebiotics that a person’s existing ecosystem can’t ferment, or fiber types that don’t reach the right bacteria), leading to poor or inconsistent metabolite signaling.
    • Applying standard timing/meal-size recommendations without aligning with postprandial glucose spikes that may be amplified by the person’s specific gut fermentation and enteroendocrine responses.
    • Overlooking tolerability and adherence issues (e.g., gastrointestinal side effects from generic prebiotic/fiber boosters in pregnancy), which can limit consistent exposure needed to shift microbiome function.

What to do

  • General support strategies

    For pregnancy-related dysglycemia and gestational diabetes risk, a core gut-focused strategy is to support a resilient microbiome that favors efficient glucose handling. Because placental hormones increase insulin resistance during pregnancy, the goal is to minimize additional microbiome-driven disruption by emphasizing dietary fiber and plant diversity—patterns such as Mediterranean-style eating with vegetables, legumes, whole grains, nuts, and seeds help feed beneficial bacteria and promote a healthier fermentation environment. This can support more favorable short-chain fatty acid (SCFA) production—particularly butyrate, acetate, and propionate—which help regulate glucose metabolism, strengthen gut barrier function, and support insulin sensitivity.

    Gut barrier health and inflammation modulation are also key general targets. When microbial balance shifts, gut permeability can increase and contribute to low-grade inflammatory signaling that interferes with insulin pathways. Supporting gut integrity through fiber-rich, minimally processed foods (and, where appropriate, adequate hydration and consistent meal patterns) may help reduce inflammatory pressure and blunt post-meal glucose spikes. In parallel, maintaining a diet that supports healthy bile acid metabolism and enteroendocrine signaling is beneficial, since gut microbes influence bile acid profiles and microbial metabolites that affect metabolic receptors involved in glucose homeostasis and insulin release.

    Overall, these nutrition-first strategies are most effective when paired with practical consistency: gradual improvements in fiber intake, attention to carbohydrate quality (choosing high-fiber, whole-food carbohydrates over refined sugars), and a regular eating cadence that avoids large glucose excursions. While individual needs vary during pregnancy, the general support approach centers on nourishing a microbiome capable of producing beneficial metabolites, maintaining barrier integrity, and supporting metabolic signaling pathways that together can improve fasting and postprandial glucose control.

  • Lifestyle recommendations

    • Prioritize a high-fiber, Mediterranean-style diet (plenty of vegetables, legumes, whole grains, nuts/seeds) to support beneficial SCFA-producing gut microbes.
    • Choose carbohydrates with a low glycemic impact (e.g., intact whole grains, beans, non-starchy vegetables) and pair them with protein and healthy fats to reduce post-meal glucose spikes.
    • Aim for consistent meal timing and include balanced snacks when needed to avoid large swings in fasting and postprandial glucose.
    • Engage in pregnancy-safe physical activity most days (e.g., walking after meals, as approved by your clinician) to improve insulin sensitivity and gut metabolic signaling.
    • Stay hydrated and limit added sugars and refined starches (sweets, sugary drinks, white bread/pastries) to reduce glucose excursions and downstream gut inflammatory signals.
    • Use evidence-based prenatal supplements only as directed (e.g., fiber goals via food, and probiotics only if appropriate for your situation and clinician guidance) rather than starting aggressive gut interventions on your own.

  • Nutrition recommendations

    • Prioritize high-fiber, minimally processed carbs (e.g., legumes, oats, barley, vegetables, berries) to support beneficial SCFA production (acetate/propionate/butyrate) and improve post-meal glucose handling.
    • Adopt a Mediterranean-style eating pattern: emphasize extra-virgin olive oil, nuts/seeds, fish, and a wide variety of plant foods; limit added sugars, refined grains, and ultra-processed foods that can destabilize the microbiome and glycemic control.
    • Choose carbs with lower glycemic impact and pair them with protein and healthy fats at meals (e.g., Greek yogurt or eggs + nuts; lentils + olive oil + leafy greens) to blunt glucose spikes and support gut metabolic signaling.
    • Increase fermented and probiotic foods as tolerated (e.g., unsweetened yogurt/kefir, fermented vegetables like sauerkraut/kimchi) to encourage a more supportive microbial community; avoid versions with added sugar.
    • Support bile acid–gut signaling with steady, fiber-rich intake and adequate hydration; avoid “fiber-cycling” (swinging from very low to very high fiber) and aim for consistent daily plant variety.
    • Use carbohydrate distribution strategies: spread intake across meals/snacks and avoid large late-night carb loads to reduce overall glycemic excursions that can worsen insulin resistance during pregnancy.

  • Supplement considerations

    For pregnancy-related dysglycemia, supplement strategies often focus on supporting a gut ecosystem that favors insulin sensitivity and healthier metabolic signaling. Because many beneficial effects are thought to relate to microbial fermentation of fiber, nutrients that help increase or mimic gut-derived short-chain fatty acids (SCFAs)—notably butyrate, acetate, and propionate—are commonly considered. This includes options such as butyrate (sometimes via delayed-release forms), acetate/propionate precursors, and fiber-focused approaches that act as prebiotics to encourage SCFA-producing bacteria. The goal is to improve metabolic resilience by supporting gut barrier integrity and reducing gut-driven low-grade inflammation, both of which can worsen insulin signaling during pregnancy.

    Bile acids and enteroendocrine signaling are another major gut-linked pathway in dysglycemia. Certain supplements may influence bile acid metabolism indirectly by shifting microbial activity, and some approaches use bile-acid–supporting compounds (or combinations designed to improve microbiome–bile acid cross-talk). In addition, probiotics and probiotic-derived products (e.g., specific strains with evidence related to glucose handling, or postbiotics such as targeted metabolites) are sometimes considered to support a more favorable community structure. However, pregnancy is a unique physiologic state, so product selection matters: look for well-characterized strains, safety data in pregnancy, and transparent dosing rather than “proprietary blends” with limited evidence.

    Because diet is a primary driver of the microbiome, supplements are usually most helpful when they complement a Mediterranean-style pattern rich in diverse plant fibers, legumes, and minimally processed foods. Timing may also be relevant—for example, taking prebiotic-type supplements with meals can sometimes improve tolerance and may align with post-meal glucose regulation targets. If using any supplement during pregnancy, it’s important to coordinate with an obstetric or diabetes-care clinician, especially in the setting of diagnosed GDM or borderline screening results, to ensure compatibility with prenatal care and to avoid confounding glucose monitoring.

  • Retesting / monitoring note

    Retesting is typically considered after any pregnancy-related dysglycemia screening result that is borderline or positive for gestational diabetes (GDM), or after dietary/lifestyle changes are implemented that could reasonably influence glucose regulation. In many clinical settings, this means following up with the next guideline-based step (for example, completing the recommended confirmatory test if an initial screen was abnormal). If the initial abnormality is mild or equivocal, your clinician may also consider repeating testing after a short interval to ensure the result reflects true glycemic status rather than day-to-day variability.

    Because gut-related factors are increasingly recognized as contributors to insulin resistance in pregnancy—largely through shifts in short-chain fatty acid (SCFA) production, inflammation signaling, and bile acid–enteroendocrine pathways—retesting can be used to evaluate whether the body’s glucose control improves with a gut-supportive approach. This is especially relevant when interventions focus on increasing fiber-rich, minimally processed foods (often Mediterranean-style patterns), reducing added sugars, and supporting consistent carbohydrate quality. If you have made meaningful dietary changes and your symptoms (such as post-meal glucose spikes) have improved, retesting can help confirm whether glycemic control has moved toward normal.

    Timing matters: retesting is usually scheduled to coincide with the pregnancy window when insulin resistance tends to peak and when most guideline-based screening is performed. Your clinician will also consider factors like gestational age, prior glucose results, and whether there are risk factors such as prior GDM, family history of type 2 diabetes, or evidence of worsening symptoms. After delivery, additional testing is often recommended to check for persistent dysglycemia, since pregnancy-related changes can unmask longer-term metabolic risk that may relate to lasting microbiome and metabolic pathway shifts.

The importance of gut microbiome testing

  • Why testing matters

    Pregnancy-related dysglycemia is influenced by more than circulating hormones—your gut microbiome can meaningfully affect how efficiently your body handles glucose. During pregnancy, placental hormones increase insulin resistance as part of normal physiology, and for some individuals the gut ecosystem shifts in ways that further worsen glucose control. Gut microbiome testing matters because it can reveal whether your microbial community resembles patterns seen in gestational diabetes (GDM) risk versus those associated with normal glucose regulation, helping you understand what may be driving higher fasting glucose, stronger post-meal glucose spikes, or difficulty maintaining stable energy levels.

    Testing is also valuable because it can help you infer functional pathways tied to insulin sensitivity, particularly short-chain fatty acid (SCFA) production. Beneficial bacteria that ferment dietary fiber support the generation of metabolites like butyrate, acetate, and propionate, which can improve gut barrier integrity, reduce inflammatory signaling, and support more effective insulin signaling. A less favorable microbiome profile may correspond to lower or altered SCFA output, greater gut permeability, and low-grade inflammation—mechanisms that can amplify insulin resistance during pregnancy. Microbiome testing can therefore guide targeted dietary strategies aimed at restoring a metabolite profile that supports steadier blood sugar.

    Finally, gut microbes interact with bile acid metabolism and enteroendocrine signaling, both of which play roles in glucose homeostasis and insulin release. Because microbial metabolites can influence metabolic receptors and hormone pathways that regulate appetite and glucose absorption, identifying your baseline gut characteristics can help personalize nutrition choices that shape bile acid and signaling dynamics. In practice, this means microbiome-aware adjustments—often emphasizing high-fiber, diverse, plant-rich patterns such as Mediterranean-style eating—may be more effective when guided by your specific test findings rather than relying on one-size-fits-all recommendations.

  • How InnerBuddies helps

    InnerBuddies helps women with pregnancy-related dysglycemia by looking at the gut microbiome patterns that influence glucose regulation during this period of naturally increased insulin resistance. Because certain microbial community structures are more commonly observed in people who develop gestational diabetes (GDM), the test can help clarify whether your gut ecosystem leans toward pathways associated with steadier glucose control or toward those linked with higher fasting glucose and more pronounced post-meal blood sugar spikes. This can be especially useful when your lab results fall into a borderline range or when symptoms like thirst, fatigue, or transient vision changes suggest that glucose swings may be occurring.

    Beyond community composition, InnerBuddies supports interpretation of gut-function drivers that matter for insulin sensitivity—particularly microbial fermentation and short-chain fatty acid (SCFA) production. SCFAs such as butyrate, acetate, and propionate are generated when gut bacteria break down dietary fiber, and they play roles in supporting gut barrier integrity, dampening low-grade inflammation, and improving insulin signaling. By identifying whether your microbiome aligns with a fiber-fermenting, SCFA-supportive profile (or a less favorable one), InnerBuddies can help you target dietary changes aimed at reducing gut-related inflammation and improving metabolic stability.

    InnerBuddies can also shed light on gut–bile acid and enteroendocrine signaling pathways that affect glucose homeostasis. Microbes can modify bile acids and generate metabolites that interact with metabolic receptors involved in insulin sensitivity and hormone signaling. Understanding your baseline microbiome characteristics therefore helps make nutrition guidance more personalized—for example, emphasizing a Mediterranean-style, high-fiber, plant-diverse pattern that supports healthier bile acid metabolism and more effective insulin release during pregnancy.

Medical Evidence

  • Scientific evidence level

    2 [weak—emerging but inconsistent; mainly association/biological plausibility with limited causal and no validated clinical utility]

  • Clinical relevance note

    At present, microbiome–pregnancy dysglycemia research has moderate biological plausibility and some observational support, but the overall evidence is not yet strong enough to change clinical practice. Statistically significant associations between gut microbial patterns and dysglycemia/GDM risk are reported, yet reproducibility across studies is limited and confounding/reverse causality are major concerns. Pregnancy is a rapidly changing, highly diet- and hormone-influenced state, which complicates inference about directionality.

    Clinical relevance is therefore low-to-early: microbiome signatures are best viewed as hypothesis-generating biomarkers for future risk stratification research, not validated clinical diagnostics. Intervention evidence (probiotics/prebiotics/diet with microbiome effects) remains inconsistent, and RCTs have not conclusively demonstrated that microbiome modulation produces clinically meaningful improvements in dysglycemia outcomes with clear mechanistic microbial mediation and generalizable protocols. A practical takeaway is that routine gut microbiome testing or microbiome-targeted therapy for pregnancy-related dysglycemia is not evidence-based at this time.


Below is a list of the most important medical publications linked to this specific condition.

Title Journal Year Link
Microbiome and metabolic health during pregnancy and postpartum: a systematic review and meta-analysis Gut Microbes 2021 —
The maternal gut microbiome and the risk of gestational diabetes mellitus: a prospective cohort study Nature Communications 2018 —
Altered gut microbiota in pregnant women with gestational diabetes mellitus Diabetes 2016 —
Fecal microbiota signatures are associated with gestational diabetes mellitus Genome Medicine 2012 —
Gut microbiome composition and function influence glucose metabolism in mice Nature Medicine 2010 —

Frequently Asked Questions

    What is pregnancy-related dysglycemia and how might the gut microbiome be involved?
    Pregnancy-related dysglycemia ranges from impaired glucose tolerance to gestational diabetes (GDM). The gut microbiome may influence insulin resistance, inflammation, gut barrier function, bile acids, and short-chain fatty acid (SCFA) production, all of which can affect glucose control. This is general information and not a diagnosis; discuss testing and care with your clinician.
    How does the gut microbiome influence insulin resistance during pregnancy?
    Diet-shaped gut microbes can alter SCFAs, gut permeability, inflammation, bile acid signaling, and enteroendocrine pathways, which can affect insulin action and glucose regulation in pregnancy. This is general information and not a diagnosis; talk to your healthcare provider about your situation.
    What are SCFAs, and why are butyrate, acetate, and propionate important for glucose control in pregnancy?
    SCFAs are short-chain fatty acids produced when gut bacteria ferment dietary fiber. Butyrate, acetate, and propionate help support the gut barrier, reduce inflammation, and improve insulin signaling, which can influence glucose tolerance during pregnancy. This is general information and not a diagnosis; consult your clinician for interpretation and guidance.
    What are common symptoms of pregnancy-related dysglycemia?
    Possible symptoms include higher fasting glucose, higher post-meal glucose, increased insulin resistance, thirst and frequent urination, fatigue, and sometimes blurred vision. This is general information and not a diagnosis; seek medical evaluation if concerned.
    How common is gestational diabetes, and what risk factors increase susceptibility?
    GDM affects roughly 5–14% of pregnancies worldwide. Higher risk is linked to prior dysglycemia, higher pre-pregnancy BMI, family history of type 2 diabetes, and certain ethnic backgrounds. This is general information and not a diagnosis; discuss risk with your clinician.
    Which gut bacteria are commonly reduced or elevated in GDM risk?
    Low-benefit taxa may include Akkermansia muciniphila, Faecalibacterium prausnitzii, Roseburia spp., Butyricicoccus pullicaecorum, Eubacterium rectale, Bifidobacterium spp., Blautia spp., Christensenellaceae (family). Elevated taxa can include Enterococcus spp., Streptococcus spp., Ruminococcus gnavus group, Parabacteroides spp., Dialister spp., Bacteroides spp., Escherichia/Shigella, and some Actinobacteria (e.g., Adlercreutzia spp.). This is general information and not a diagnosis; discuss findings with a clinician.
    How can diet influence the gut microbiome to support glucose regulation in pregnancy?
    A fiber- and plant-diverse diet supports beneficial microbes, SCFA production, gut barrier function, and healthier bile acid signaling. Mediterranean-style patterns are often recommended for gut and metabolic health during pregnancy. This is general guidance and not a diagnosis; tailor choices with your healthcare provider.
    Should I consider a gut microbiome test to assess my risk? What should I know about testing?
    Microbiome testing is still emerging and not routinely used to diagnose GDM. It may reveal baseline patterns and related pathways, but results should be discussed with a clinician in the context of standard screening. This is general information and not a diagnostic recommendation.
    How could microbiome results guide dietary choices during pregnancy?
    If results suggest a fiber-fermenting, SCFA-supportive profile, you might focus on fiber-rich, diverse plant foods. If the profile is less favorable, the goal may be to support SCFA-producing microbes through similar dietary patterns, always under medical supervision. This is general information and not a diagnosis.
    What roles do bile acids and enteroendocrine signaling play in glucose metabolism during pregnancy?
    Microbes modify bile acids that can activate receptors influencing insulin sensitivity. Microbial metabolites can also affect hormone pathways that regulate appetite, insulin release, and glucose absorption. This is general information and not medical advice; discuss with your clinician.
    How should I discuss gut microbiome and dysglycemia with my healthcare provider?
    Share symptoms, family history, prior dysglycemia, and interest in nutrition strategies. Ask about standard screening results and whether microbiome testing is appropriate for you and how results would be used in care. This is general information and not a diagnosis.
    What is InnerBuddies, and how does it relate to this topic?
    InnerBuddies is described as a program to help interpret gut microbiome patterns and pathways related to glucose regulation during pregnancy and guide dietary suggestions; it does not replace medical advice. This is general information and not a medical recommendation.

    Gut Microbiome and Pregnancy-related dysglycemia

    →

    Gut Microbiome and Gestational diabetes

    →

    Gut Microbiome and Maternal microbiome / infant health

    →

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -